The selective ablation of inflammation in an acute stage of ischemic stroke may be a new strategy to promote neurogenesis.

Abstract

Ischemic stroke is one of the most common diseases in the world. Pre-clinical studies have proved that stem cell therapy is effective in treating ischemic stroke. But there is a "time window" for stem cell therapy that is only limited in acute/subacute stage after stroke. Meanwhile, ischemic stroke can elicit an immediate neuroinflammatory reaction in the brain, and an uncontrolled inflammatory process in acute/subacute stage will impair survival of stem cells and block repair processes. A selective ablation of harmful inflammation factors can greatly decrease a hostile environment and facilitate neurogenesis. If detrimental factors of inflammation in an acute/subacute stage after an ischemic stroke are suitably handled and more specific immunomodulatory interventions are adopted, neurogenesis in the "time window" will greatly enhanced.

• Authors: Jie Zhou, Gang Cheng, Ronghua Kong, Da-Kuan Gao, Xiang Zhang
• Journal: Medical hypotheses (Med Hypotheses) Vol. 76 Issue 1 Pg. 1-3 (Jan 2011) ISSN: 1532-2777 [Electronic] United States
• PMID: 21112156 (Publication Type: Journal Article)
• Copyright: Copyright © 2010 Elsevier Ltd. All rights reserved.

Topics

• Animals
• Brain Ischemia (pathology)
• Humans
• Inflammation (pathology, therapy)
• Neurogenesis
• Rats
• Stroke (pathology)